[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.17.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 864
Citations 0
News From the Food and Drug Administration
December 1, 2015

Anticoagulant Can Be Reversed

JAMA. 2015;314(21):2227. doi:10.1001/jama.2015.16164

A newly approved drug is available to reverse the blood-thinning effects of dabigatran, marketed as Pradaxa, in emergency or life-threatening situations when bleeding can’t be controlled.

Idarucizumab, sold under the brand name Praxbind, binds specifically to dabigatran molecules and neutralizes their anticoagulant effect without interfering with the coagulation cascade. The drug is a monoclonal antibody fragment given intravenously (http://1.usa.gov/1PmI9P6).

First Page Preview View Large
First page PDF preview
First page PDF preview
×